Retrospective study demonstrates ctDNA profiling detects genomic changes faster in biliary tract cancer, suggesting its clinical utility.
Circulating tumor DNA (ctDNA) profiling detects actionable genomic alterations in advanced biliary tract cancer faster (8 vs 27 days) and more often (90% vs 50%) than tissue, with high concordance. A recent retrospective study establishes clinical validity and a compelling access case for future prospective ctDNA-directed trials.
No takes yet. Share an insight, caveat, or question.
Au et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: